The latest price target for NeuroBo Pharmaceuticals (NASDAQ:NRBO) was reported by Maxim Group on May 8, 2024. The analyst firm set a price target for $10.00 expecting NRBO to rise to within 12 months (a possible 138.10% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for NeuroBo Pharmaceuticals (NASDAQ:NRBO) was provided by Maxim Group, and NeuroBo Pharmaceuticals initiated their buy rating.

There is no last upgrade for NeuroBo Pharmaceuticals

There is no last downgrade for NeuroBo Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroBo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroBo Pharmaceuticals was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.

While ratings are subjective and will change, the latest NeuroBo Pharmaceuticals (NRBO) rating was a initiated with a price target of $0.00 to $10.00. The current price NeuroBo Pharmaceuticals (NRBO) is trading at is $4.20, which is within the analyst’s predicted range.